[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 844 Engrossed in House (EH)]
H. Res. 844
In the House of Representatives, U.S.,
July 28, 2006.
Whereas HIV/AIDS has killed over 25,000,000 people worldwide and poses a serious
threat to the economic and political stability of the countries hit
hardest by this terrible epidemic;
Whereas the International AIDS Vaccine Initiative (IAVI) was founded in 1996 as
a public-private partnership with a mission to ensure the development of
safe, effective, accessible, preventive HIV/AIDS vaccines for use
throughout the world, with a particular focus on developing countries,
where the need is most urgent;
Whereas the International AIDS Vaccine Initiative's research and policy programs
have galvanized scientific efforts and substantially increased financial
and political support for this vital effort;
Whereas since its founding, the International AIDS Vaccine Initiative has
advanced six vaccine candidates from concept to clinical trials,
targeting the subtypes of HIV circulating in the developing world--a
record matched only by one large pharmaceutical company;
Whereas ten years ago only a few developing countries had participated in HIV/
AIDS vaccine trials, but today several countries in sub-Saharan Africa
and Asia are actively participating in HIV/AIDS vaccine trials, a
reflection of the International AIDS Vaccine Initiative's activism and
commitment to working collaboratively with developing country partners;
Whereas the model of the International AIDS Vaccine Initiative, which closely
links clinical trial site investigators to product developers, has
resulted in the first HIV/AIDS vaccine trials being conducted in Kenya,
Rwanda, and India, as well as trials in Uganda and South Africa;
Whereas the International AIDS Vaccine Initiative is a founding member of the
Global HIV/AIDS Vaccine Enterprise, recognized by the G-8 as an
important actor in the quest for a vaccine; is an affiliated member of
the National Institutes of Health's Partnership for AIDS Vaccine
Evaluation; and is hosting NIH trials at International AIDS Vaccine
Initiative sites in Africa;
Whereas the International AIDS Vaccine Initiative's Core Clinical Immunology
Laboratory was the first Good Clinical Laboratory Practices (GCLP)
accredited laboratory in the world to assess HIV/AIDS vaccines, and the
International AIDS Vaccine Initiative's laboratory in Uganda was the
first to receive such accreditation in Africa; and
Whereas the International AIDS Vaccine Initiative established a ground-breaking
Neutralizing Antibody Consortium to address one of the key scientific
challenges to vaccine design: Now, therefore, be it
Resolved, That the House of Representatives--
(1) congratulates the International AIDS Vaccine Initiative on ten
years of significant achievement in the search for an HIV/AIDS vaccine;
(2) recognizes the role of the International AIDS Vaccine Initiative
in raising awareness and increasing financial and political support for
this important cause;
(3) admires the commitment of the International AIDS Vaccine
Initiative to collaborating with developing country researchers,
governments, and civil society in the common goal of finding a vaccine;
(4) expresses support for the continued success of the International
AIDS Vaccine Initiative; and
(5) directs the Clerk of the House of Representatives to transmit an
enrolled copy of this resolution to the International AIDS Vaccine
Initiative.
Attest:
Clerk.